Atlas Arteria (OTCMKTS:MAQAF) Shares Down 16.3% – Time to Sell?

Atlas Arteria Limited (OTCMKTS:MAQAF – Get Free Report)’s stock price was down 16.3% during mid-day trading on Tuesday . The company traded as low as $3.08 and last traded at $3.08. 200 shares changed hands during trading, a decline of 84% from the average session volume of 1,235 shares. The stock had previously closed at $3.68.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on MAQAF shares. Jefferies Financial Group raised Atlas Arteria to a “buy” rating and set a $5.31 target price on the stock in a research note on Thursday, August 27th. Royal Bank Of Canada cut shares of Atlas Arteria to an “underperform” rating and set a $4.75 price target on the stock. in a research note on Thursday, July 2nd. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Atlas Arteria currently has a consensus rating of “Hold” and an average price target of $5.03.

View Our Latest Report on MAQAF

Atlas Arteria Stock Performance

The company’s 50-day moving average is $3.45 and its two-hundred day moving average is $3.38.

Atlas Arteria Company Profile

(Get Free Report)

Atlas Arteria (OTCMKTS:MAQAF) is an international toll-road owner and operator headquartered in Australia. Through its portfolio of infrastructure investments, the company manages and operates road networks that generate revenue from electronic and conventional tolling, while providing motorists with access to major transport corridors.

The company’s principal interests include toll-road assets in France, Germany and the United States. Its French operations include interests in the APRR and AREA motorway networks, which connect major cities and commercial regions across eastern and southeastern France.

Recommended Stories

Receive News & Ratings for Atlas Arteria Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atlas Arteria and related companies with MarketBeat.com's FREE daily email newsletter.